[1] SALVADOR GL, MARMENTINI VM, COSMO WR, et al. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: systematic review and meta-analysis[J]. Eur J Prev Cardiol, 2017, 24(18): 1914. doi: 10.1177/2047487317728766
[2] BAO X, ZHU W, ZHANG R, et al. Synthesis and evaluation of novel angiotensin Ⅱ receptor 1 antagonists as anti-hypertension drugs[J]. Bioorg Med Chem, 2016, 24(9): 2023. doi: 10.1016/j.bmc.2016.03.028
[3] WATANABE R, SUZUKI JI, WAKAYAMA K, et al. Angiotensin Ⅱ receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure[J]. Hypertens Res, 2016, 39(4): 237. doi: 10.1038/hr.2015.141
[4] 张源波, 李海明, 杨萌, 等. 利尿钠肽及肾素-血管紧张素-醛固酮系统对高血压的影响[J]. 中国循证心血管医学杂志, 2017, 9(11): 129.
[5] 岳薇薇, 胡大春. 肾素-血管紧张素-醛固酮系统在高血压遗传病理机制中的研究进展[J]. 医学综述, 2018, 24(22): 4440. doi: 10.3969/j.issn.1006-2084.2018.22.014
[6] 赵耀武, 艾力江·热西提, 李熙. 继发性高血压患者尿微量蛋白含量与肾素-血管紧张素-醛固酮系统中肾素的关系研究[J]. 中华养生保健, 2020, 38(2): 94.
[7] HASS A, OZ H, MASHAVI M, et al. Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin Ⅱ receptor blocker on adipokines level in hypertensive patients[J]. J Am Soc Hypertens, 2014, 8(10): 709. doi: 10.1016/j.jash.2014.07.033
[8] AMEER OZ, BUTLIN M, KASCHINA E, et al. Long-term angiotensin Ⅱ receptor blockade limits hypertension, aortic dysfunction, and structural remodeling in a rat model of chronic kidney disease[J]. J Vasc Res, 2016, 53(3/4): 216.
[9] LIN J, LIN S, WU Y, et al. Hypomethylation of the angiotensin Ⅱ type Ⅰ receptor (AGTR1) gene along with environmental factors increases the risk for essential hypertension[J]. Cardiology, 2017, 137(2): 126. doi: 10.1159/000458520
[10] SINGH A, SRIVASTAVA N, YADAV A, et al. Targeting AGTR1/NF-κB/CXCR4 axis by miR-155 attenuates oncogenesis in glioblastoma[J]. Neoplasia, 2020, 22(10): 497. doi: 10.1016/j.neo.2020.08.002
[11] YANG Y, ZHOU Y, CAO Z, et al. miR-155 functions downstream of angiotensin Ⅱ receptor subtype 1 and calcineurin to regulate cardiac hypertrophy[J]. Exp Ther Med, 2016, 12(3): 1556. doi: 10.3892/etm.2016.3506